About the Program:
Program Overview:
The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016). This program consists of four components: (1) CME Internet Symposium: EASL 2016 Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium; (3) Rapid-Fire Review of EASL 2016: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference To Clinic: Reviewing And Applying Data From EASL 2016: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.
The Rapid-Fire Review of EASL 2016 features Dr. Mark Sulkowski briefly reviewing the the most essential information and
data from EASL 2016.
This activity will enable participating health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All online components of the program can be accessed at www.viraled.com.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EASL 2016 and it is not sanctioned by the organizers of EASL 2016.
Target Audience:
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.
Learning Objectives:
After completing this activity, the participant should be better able to:
-
Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at EASL 2016
-
Employ the current treatment paradigms for CHC, including the studies and data presented at EASL 2016 to improve patient care
- Discuss with patients and colleagues the studies and data on newer therapies for CHC presented at EASL 2016 to decide on appropriate planning of therapy for patients with CHC
Release Date: April 20, 2016
Expiration Date: April 20, 2017
Estimated time to complete the Podcast: 45 minutes
Media: Internet
Faculty:
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd,Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this
activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary
business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Dr. Mark Sulkowski:
- Contracted Research: AbbVie; Gilead; Janssen; Merck (to JHU)
- Consulting Fees: Abbvie; Crystal; Gilead; Janssen; Merck; Trek
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, race Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP and Jan Shultz, RN, MSN, CHCP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planner. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and
warnings.
Instructions for Participation and Credit:
There are no fees for participating and receiving CME credit for this activity. During the period, April 20, 2016 through April 20, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation
by Course" and search by course ID 11385. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount
of paper used by nearly 100,000 sheets per year.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.
Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by
clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable
manufacturer’s product information, and comparison with recommendations of other authorities.
Supported by an independent educational grant from Gilead Sciences Medical Affairs.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EASL 2016 and it is not sanctioned by EASL 2016.
| 